|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...2829303132333435363738...6768» |
- | human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap
Trial completion, Post-transplantation: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (clinicaltrials.gov) - Oct 27, 2014
P1, N=30, Completed, Sponsor: Cellerant Therapeutics
Active, not recruiting --> Completed
- bortezomib / Generic mfg., cyclophosphamide / Generic mfg.
Trial initiation date, Trial primary completion date: Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 24, 2014
P2, N=43, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Initiation date: May 2014 --> Apr 2015 | Trial primary completion date: Jul 2015 --> Aug 2016
- || Trial primary completion date: A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=1800, Recruiting, Sponsor: Swedish Orphan Biovitrum
Initiation date: May 2014 --> Apr 2015 | Trial primary completion date: Jul 2015 --> Aug 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial initiation date, Trial suspension, Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Oct 22, 2014
P2, N=30, Suspended, Sponsor: mamdouh abdulmaksoud abdulrhman
Trial primary completion date: Dec 2014 --> Dec 2015 Initiation date: Jan 2012 --> Oct 2014 | Not yet recruiting --> Suspended | Trial primary completion date: Jun 2012 --> Nov 2014
- | bortezomib / Generic mfg.
Trial completion, Trial primary completion date: Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients (clinicaltrials.gov) - Oct 22, 2014
P2, N=17, Completed, Sponsor: University of Utah
Initiation date: Jan 2012 --> Oct 2014 | Not yet recruiting --> Suspended | Trial primary completion date: Jun 2012 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Sep 2014
- || Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date, Combination therapy: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2014
P2, N=102, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Sep 2014 Trial primary completion date: Dec 2014 --> Mar 2015
- | lenalidomide / Generic mfg., thalidomide / Generic mfg., pomalidomide / Generic mfg.
Clinical: Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma (clinicaltrials.gov) - Oct 22, 2014
P3, N=172, Terminated, Sponsor: Celgene Corporation
Trial primary completion date: Dec 2014 --> Mar 2015 Not yet recruiting --> Terminated; The study was terminated due to poor feasibility and lack of interest at the participating sites.
- Trial primary completion date, HEOR: Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=300, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Terminated; The study was terminated due to poor feasibility and lack of interest at the participating sites. Trial primary completion date: Jul 2014 --> Nov 2014
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial primary completion date: Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) - Oct 20, 2014
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Nov 2014 Trial primary completion date: Feb 2015 --> Apr 2017
- || Trial primary completion date: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: University of Arkansas
Trial primary completion date: Feb 2015 --> Apr 2017 Trial primary completion date: Mar 2014 --> Mar 2015
- ||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Oct 20, 2014
P3, N=62, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Mar 2015
- |||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Trial completion, Preclinical, Enrollment change, Trial primary completion date: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Oct 20, 2014
P4, N=57, Completed, Sponsor: CSL Behring
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Mar 2015 Recruiting --> Completed | N=150 --> 57 | Trial primary completion date: Sep 2015 --> Sep 2014
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 20, 2014
P0, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed | N=150 --> 57 | Trial primary completion date: Sep 2015 --> Sep 2014 Phase classification: P=N/A --> P0
- | bortezomib / Generic mfg.
New P4 trial: A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma (clinicaltrials.gov) - Oct 20, 2014
P4, N=18, Not yet recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
- || Trial primary completion date: A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure (clinicaltrials.gov) - Oct 17, 2014
P4, N=2399, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Phase classification: P=N/A --> P0 Trial primary completion date: Sep 2015 --> Oct 2014
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial initiation date: A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=10, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2015 --> Oct 2014 Initiation date: Jun 2013 --> Oct 2014
- || hydrocortisone / Generic mfg.
New P3 trial: Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock (clinicaltrials.gov) - Oct 17, 2014
P3, N=84, Completed, Sponsor: Nanjing PLA General Hospital
- | Mozobil (plerixafor) / Sanofi
Enrollment open: Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2014
P2, N=14, Recruiting, Sponsor: Genzyme, a Sanofi Company
Initiation date: Jun 2013 --> Oct 2014 Not yet recruiting --> Recruiting
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=25, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2016
- Trial primary completion date: UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2014
P2, N=233, Active, not recruiting, Sponsor: University of Arkansas
Trial primary completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Dec 2013 --> Dec 2015
- Trial termination: Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (clinicaltrials.gov) - Oct 17, 2014
P2, N=10, Terminated, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2013 --> Dec 2015 Completed --> Terminated; Due to the high rate of morbidity and mortality
- Rituxan (rituximab) / Roche
Phase classification, Combination therapy: Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Oct 17, 2014
P0, N=22, Completed, Sponsor: Mayo Clinic
Completed --> Terminated; Due to the high rate of morbidity and mortality Phase classification: P=N/A --> P0
- | Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Phase classification: Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy (clinicaltrials.gov) - Oct 17, 2014
P2, N=320, Completed, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P0 Phase classification: P=N/A --> P2
- warfarin / Generic mfg.
New P1/2 trial: Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=40, Not yet recruiting, Sponsor: McMaster University
- Promacta (eltrombopag) / Novartis
Enrollment closed: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 17, 2014
P2, N=24, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Phase classification: P=N/A --> P2 Recruiting --> Active, not recruiting
- New P3 trial: A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B (clinicaltrials.gov) - Oct 15, 2014
P3, N=0, Completed, Sponsor: Bio Products Laboratory
- New P3 trial: A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years (clinicaltrials.gov) - Oct 15, 2014
P3, N=0, Completed, Sponsor: Bio Products Laboratory
- bortezomib / Generic mfg.
Trial primary completion date: Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) - Oct 15, 2014
P0, N=15, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2013 --> Apr 2015
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 15, 2014
P1/2, N=81, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2013 --> Apr 2015 Trial primary completion date: Aug 2012 --> Apr 2012
- | Trial completion: Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor (clinicaltrials.gov) - Oct 15, 2014
P2, N=28, Completed, Sponsor: Thomas Jefferson University
Trial primary completion date: Aug 2012 --> Apr 2012 Active, not recruiting --> Completed
- Enrollment closed: Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=75, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 10, 2014
P1/2, N=32, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=52 --> 32
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment status, Phase classification: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Oct 10, 2014
P4, N=200, Enrolling by invitation, Sponsor: Pfizer
N=52 --> 32 Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4
- || BeneFix (nonacog alfa) / Pfizer
Enrollment status, Phase classification, Adverse events: Registry For Patients Treated With BeneFix In Usual Care Setting In Germany (clinicaltrials.gov) - Oct 10, 2014
P4, N=100, Enrolling by invitation, Sponsor: Pfizer
Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Oct 10, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 Trial primary completion date: Oct 2015 --> Feb 2016
- roneparstat (LB401) / Leadiant Biosci
Trial primary completion date, Metastases: SST0001 (Roneparstat) in Advanced Multiple Myeloma (clinicaltrials.gov) - Oct 10, 2014
P1, N=30, Recruiting, Sponsor: Sigma Tau Research Switzerland SA
Trial primary completion date: Oct 2015 --> Feb 2016 Trial primary completion date: Oct 2014 --> Oct 2015
- | Innohep (tinzaparin) / LEO Pharma
New P2 trial: METRO B: Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer (clinicaltrials.gov) - Oct 10, 2014
P2, N=24, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- ||| Zarxio (filgrastim-sndz) / Novartis
Trial completion, Trial primary completion date: Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=1500, Completed, Sponsor: Sandoz
Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2013
- Trial primary completion date: PUCHS: Project to Update the Study of Congenital Haemophilia in Spain (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=2500, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2013 Trial primary completion date: Sep 2014 --> Dec 2014
- Enrollment open, Heterogeneity: Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=40, Recruiting, Sponsor: CancerCare Manitoba
Trial primary completion date: Sep 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- Xyntha (moroctocog alfa) / Pfizer
P4 data, Phase classification: Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A (clinicaltrials.gov) - Oct 2, 2014
P4, N=43, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P4
- Clinical: Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: University of Valencia
- bortezomib / Generic mfg.
Trial primary completion date: UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - Oct 2, 2014
P2, N=30, Active, not recruiting, Sponsor: University of Arkansas
Phase classification: P=N/A --> P4 Trial primary completion date: Dec 2013 --> Dec 2015
- Clinical: Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma (clinicaltrials.gov) - Oct 2, 2014
P1/2, N=45, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Jun 2014 --> Mar 2014
- | Odomzo (sonidegib) / Sun Pharma
New P2 trial: Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 2, 2014
P2, N=48, Not yet recruiting, Sponsor: SCRI Development Innovations, LLC
- ||||| Enrollment closed: Velcade (Bortezomib) Consolidation After Transplant (clinicaltrials.gov) - Oct 2, 2014
P3, N=247, Active, not recruiting, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Jun 2014 --> Mar 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> May 2013
- ||| Empliciti (elotuzumab) / AbbVie, BMS, lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, urelumab (BMS-663513) / BMS, Ono Pharma
New P1 trial, Combination therapy: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (clinicaltrials.gov) - Sep 30, 2014
P1, N=136, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Optivate (factor VIII/von Willebrand factor) / Bio Products Laboratory (BPL)
New P3 trial: A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A. (clinicaltrials.gov) - Sep 28, 2014
P3, N=0, Completed, Sponsor: Bio Products Laboratory
- Optivate (factor VIII/von Willebrand factor) / Bio Products Laboratory (BPL)
New P3 trial: An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients. (clinicaltrials.gov) - Sep 28, 2014
P3, N=0, Completed, Sponsor: Bio Products Laboratory